bioAffinity Technologies, Inc. (BIAFW)

NASDAQ: BIAFW · Real-Time Price · USD · Warrants
0.3011
+0.1112 (58.56%)
Apr 1, 2025, 4:00 PM EDT - Market closed
58.56%
Market Cap 4.05M
Revenue (ttm) 9.36M
Net Income (ttm) -9.04M
Shares Out 15.58M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 48,304
Open 0.2800
Previous Close 0.1899
Day's Range 0.2001 - 0.4500
52-Week Range 0.2001 - 0.4500
Beta 3.14
Analysts n/a
Price Target n/a
Earnings Date Mar 28, 2025

About BIAFW

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas. [Read more]

Sector Healthcare
Founded 2014
Employees 75
Stock Exchange NASDAQ
Ticker Symbol BIAFW
Full Company Profile

Financial Performance

In 2024, bioAffinity Technologies's revenue was $9.36 million, an increase of 269.68% compared to the previous year's $2.53 million. Losses were -$9.04 million, 13.9% more than in 2023.

News

There is no news available yet.